Kyverna Therapeutics has been sued for securities law violations. The lawsuit alleges that at the time of the company's February 2024 IPO, it knew adverse data about one of Kyverna's drug trials, which it kept from the market, in violation of federal securities laws. Those who purchased Kyverna shares traceable to the company's IPO may be eligible to recover for their losses.
Contact our attorneys for a no-cost case evaluation.